Company news
Dimerix Limited (ASX:DXB) news
Dimerix Limited news releases on 6ix. Latest, Oct 4, 2026: First Patient Reaches Four Years in DMX-200 Clinical Program
Press releases & updates
First Patient Reaches Four Years in DMX-200 Clinical Program
October 4, 2026
Dimerix Draws Down A$17M Under Non-Dilutive Funding Facility
September 22, 2026
Dimerix DMX-652 Granted Mexican Composition of Matter Patent
September 13, 2026
S&P DJI Announces September 2026 Quarterly Rebalance
September 4, 2026
DIMERIX SECURES A$34 MILLION NON-DILUTIVE FACILITY TO FUND KEY CLINICAL MILESTONES
September 3, 2026
Appendix 4E and 2026 Annual Report
August 26, 2026
Dimerix Receives US$10M Upfront Payment from Everest
August 19, 2026
Dimerix Assumes Sponsorship of US IND for New Asset DMX-652
August 16, 2026
Dimerix Presents at Bioshares Summit 2026
August 5, 2026
US Patent Granted for Dimerix New Asset DMX-652
July 22, 2026
Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline
July 17, 2026
DIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURY
July 17, 2026
Dimerix Expands Pipeline with Acquisition of Phase 2 Asset
July 16, 2026
DMX-200 Available To Patients Via Post-Trial Access Pathways
July 8, 2026
DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES
June 15, 2026
Dimerix Quarterly Activities Report and Appendix 4C
April 29, 2026
BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE
April 27, 2026
Dimerix to Conduct Review of ACTION3 Statistical Assumptions
March 15, 2026
Dimerix Phase 3 Trial Last Patient Receives First Dose
March 9, 2026
Appendix 4D and Half Year Financial Report
February 25, 2026
Quarterly Appendix 4C and Activities Report
January 28, 2026
BioMarin to acquire Dimerix US Partner, Amicus Therapeutics
December 21, 2025
DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT
December 15, 2025
DMX-200 ACTION3 Phase 3 Trial Completes Recruitment
December 14, 2025
Successful Completion of Planned IDMC Review
November 18, 2025
Successful PARASOL Collaboration Data Analysis Outcome
October 7, 2025
DMX-200 receives Orphan Drug Designation in Japan
September 29, 2025
Appendix 4E and 2025 Annual Report
August 27, 2025
Dimerix receives 1st Development Milestone payment from FUSO
June 29, 2025
ACTION3 Clinical Trial Milestone Recruitment Update
June 12, 2025
1st ACTION3 site in Japan activated and milestone triggered
May 29, 2025
Successful planned IDMC review of ACTION3 trial
May 21, 2025
Dimerix receives initial upfront payment from Amicus
May 5, 2025
Investor Webinar and Presentation
April 30, 2025
Dimerix Licenses DMX-200 in the US
April 30, 2025
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
April 30, 2025
Trading Halt
April 28, 2025
FDA confirms Proteinuria as Primary Endpoint for US approval
April 27, 2025
S&P DJI Announces March 2025 Quarterly Rebalance
March 7, 2025
Dimerix receives initial upfront payment from FUSO
March 3, 2025
Half-Year Financial Report & Appendix 4D - 31 December 2024
February 24, 2025
First Paediatric Patient Recruited for ACTION3
January 15, 2025
Dimerix enters Development and License Agreement for Japan
January 6, 2025
DMX-200 ACTION3 Phase 3 Trial Part 2 Recruitment Complete
December 29, 2024
Dimerix Receives $7.9M R&D Tax Incentive Rebate
November 14, 2024
NEPTUNE Study Network to Enhance Phase 3 Recruitment in US
October 31, 2024
Project PARASOL Update & Medical Advisory Board Appointment
October 27, 2024
ACTION3 Trial Recruitment and Multiregion Trial Site Update
September 15, 2024
First Paediatric Site Activated and Trial Update
September 11, 2024
First patient enters into Open Label Extension study
September 10, 2024